New study downplays potential risk of dementia and Alzheimer’s disease among elderly men treated with hormonal therapy for prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

The male hormone testosterone contributes to normal brain function, and some research links memory loss in older men to testosterone declines that occur naturally with aging. However, testosterone is also like jet fuel for prostate tumors, causing them to grow faster, so during cancer treatment doctors will often give hormonal therapies that suppress its activities in the body. But do those therapies increase risks for dementia and Alzheimer’s disease? Some recent reports suggest that they might, although researchers have so far been unable to prove the connection, and other studies have found no link at all.

In October, researchers published the largest study yet of hormonal therapy as a possible risk factor for dementia and Alzheimer’s disease. The researchers scoured Medicare beneficiary data for 1.2 million men aged 67 or older with prostate cancer who were treated between 2001 and 2014. Of those men, 35% were treated with hormonal therapy. Published in the prestigious Journal of Clinical Oncology, the investigation found no convincing evidence that hormonal therapy poses a meaningful risk for either dementia or Alzheimer’s disease.

Dr. Kevin Nead, a resident in radiation oncology at the University of Pennsylvania’s Perelman School of Medicine, wrote an accompanying editorial about the study. He claims it had some notable strengths, including that the Medicare data was so broad that investigators could consider other potential causes of cognitive decline apart from hormonal treatment. Nead himself published a research paper in March suggesting that hormonal therapy might be associated with increased dementia risk. On the basis of this new analysis, he now downplays those findings. Even if a relationship between hormonal therapy and cognitive decline does exist, he says, “The absolute risk is small when compared to the absolute benefit of hormonal therapy for men with prostate cancer.”

Dr. Mark Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of, says, “Every study has its methodological concerns, but this one places the issue in the proper context: there is no good reason to deny men the known benefits of hormonal therapy on the basis of vague and uncertain worries over the cognitive consequences.”

— Charles Schmidt

Commenting has been closed for this post.